However, a recent study by Mu et al. reported the results of a phase II multicenter, open-label trial evaluating the efficacy and safety of anti-PD-L1 monoclonal antibody SHR-1316 administered in combination with liposomal irinotecan and 5-fluorouracil to 23 patients with advanced ESCC as a first-line treatment. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.